** Shares of biotech investor Royalty Pharma RPRX.O fall 1.3% to $31.81
** RPRX says it is providing up to $250 mln in funding to Biogen BIIB.O to support the development of litifilimab, a potential treatment for systemic lupus erythematosus $(SLE)$ and cutaneous lupus erythematosus $(CLE.AU)$
** SLE and CLE are two forms of the autoimmune disease lupus that affect multiple organs and the skin, respectively, and is currently in late-stage trial
** RPRX says the funding will be provided over six quarters in exchange for regulatory milestones and royalties on future worldwide sales of litifilimab
** Late-stage trial data are expected between 2026 and 2027
** RPRX fell 9.8% in 2024
(Reporting by Kamal Choudhury in Bengaluru)
((Kamal.Choudhury@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。